Skip to main content

Table 4 Multivariate Cox regression analyses of the overall survival and disease-free survival according to the level of γ-GT before and after PSM

From: Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization

Characteristics OS    DFS
Before PSM After PSM Before PSM After PSM
HR (95CI) P-value HR (95CI) P-value HR (95CI) P-value HR (95CI) P-value
γ-GT ≤ 54 U/L
Tumor number (Multiple vs Single) 2.11 (1.55–2.87) < 0.001 1.97 (1.33–2.93) 0.001 2.07 (1.61–2.65) < 0.001 2.18 (1.59–2.98) < 0.001
Tumor diameter (cm) 1.11 (1.07–1.15) < 0.001 1.11 (1.05–1.17) < 0.001 1.08 (1.04–1.12) < 0.001 1.08 (1.03–1.13) 0.003
Capsule (Absent vs Present) 1.36 (1.02–1.81) 0.039 1.41 (0.95–2.09) 0.085
MVI (Absent vs Present) 1.58 (1.22–2.06) 0.001 1.57 (1.10–2.26) 0.014 1.44 (1.16–1.79) 0.001 1.45 (1.08–1.95) 0.014
PA-TACE (Yes vs No) 0.85 (0.65–1.11) 0.222 0.89 (0.64–1.23) 0.471 0.86 (0.69–1.08) 0.190 0.91 (0.71–1.18) 0.483
γ-GT > 54 U/L
TBil (μmol/L) 1.01 (1.00–1.03) 0.036 1.02 (1.01–1.04) 0.009 1.01 (1.00–1.03) 0.028 1.03 (1.01–1.05) < 0.001
AFP (> 400 vs 400 ng/mL) 1.71 (1.39–2.10) < 0.001 1.71 (1.32–2.22) < 0.001 1.43 (1.20–1.71) < 0.001 1.47 (1.18–1.84) 0.001
Tumor number (Multiple vs Single) 1.25 (1.01–1.56) 0.042 1.08 (0.82–1.42) 0.589
Tumor diameter (cm) 1.06 (1.04–1.09) < 0.001 1.07 (1.04–1.10) < 0.001 1.03 (1.01–1.05) 0.008 1.04 (1.01–1.06) 0.005
Capsule (Absent vs Present) 1.33 (1.05–1.68) 0.019 1.43 (1.05–1.95) 0.024
MVI (Absent vs Present) 1.43 (1.14–1.79) 0.002 1.21 (0.89–1.64) 0.219 1.37 (1.13–1.65) 0.001 1.19 (0.92–1.54) 0.174
PA-TACE (Yes vs No) 0.69 (0.55–0.86) 0.001 0.66 (0.52–0.85) 0.001 0.76 (0.63–0.91) 0.003 0.74 (0.60–0.92) 0.006
  1. Note: OS overall survival; DFS disease-free survival; HR hazard ratio; CI confidence interval; PSM propensity score matching; γ-GT gamma-glutamyl transferase; TBil total bilirubin; AFP alpha-fetoprotein; MVI microvascular invasion; PA-TACE postoperative adjuvant transarterial chemoembolization